Overview
Linzess is approved by the U.S. Food and Drug Administration (FDA) for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults and in children aged 7 and up. Linzess should not be used in children under 2 years of age due to the risk of serious dehydration. Linzess is also known by its drug name, linaclotide.

Linzess is a guanylate cyclase-C agonist. It is believed to work by increasing the secretion of chloride and water in the intestines, which helps soften stools and stimulate bowel movements to relieve constipation associated with IBS-C.

How do I take it?
Prescribing information states that Linzess is taken by mouth once daily on an empty stomach, at least 30 minutes before the first meal of the day. For adults with IBS-C, the recommended dosage is one capsule taken at the same time each day. The capsule should be swallowed whole and not crushed or chewed. Linzess should be taken exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Linzess include diarrhea, abdominal pain, flatulence (gas), and abdominal distension (bloating).

Rare but serious side effects may include severe diarrhea that can lead to dehydration. If severe diarrhea occurs, treatment should be stopped and the person should be rehydrated.

For more information about this treatment, visit:

Linzess (Linaclotide) Capsules, for Oral Use — AbbVie